PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice

被引:17
作者
Chen, YF
Zeng, DF
Schlegel, PG
Fidler, J
Chao, NJ
机构
[1] Stanford Univ, Div Hematol Oncol, Stanford, CA 94305 USA
[2] Stanford Univ, Div Immunol, Stanford, CA 94305 USA
[3] Stanford Univ, Div Rheumatol, Stanford, CA 94305 USA
[4] Pharmagenesis Inc, Palo Alto, CA USA
关键词
D O I
10.1182/blood.V95.2.705
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PG27, an active fraction purified from an extract of a Chinese herb, Tripterygium wilfordii hook f, was used to prevent graft-versus-host disease (GVHD) in a murine model. Lethally irradiated BALB/c (H-2(d)) recipients of B10.D2 (H-2(d)) donor grafts were given daily intraperitoneal injections of PG27 (40 mg/kg per day) for the first 35 days after transplantation. Control mice were given daily injections of solvent vehicle (Ethanol and Cremophor EL). All the control recipients (15/15) died of GVHD within 90 days, but all the recipients given prophylactic treatment with PG27(15/15) survived beyond 100 days without any signs of GVHD. Furthermore, the GVHD-free recipients were used as donors, and their bone marrow and spleen cells were transplanted into lethally irradiated normal BALB/c (same party) or lethally irradiated normal C3H (H-2(k), third party) mice. Although 10 of 10 same-party recipients survived more than 100 days without any signs of GVHD, 10 of 10 third-party C3H recipients died of GVHD within 40 days. Further studies of PG27 in the murine BCL1 leukemia/lymphoma model demonstrated that animals treated with PG27 partially retained the graft-versus-leukemia (GVL) effect of the graft without GVHD, These results suggest that treatment with PG27 induces host-specific tolerance and retains the GVL effect of allogeneic marrow grafts.
引用
收藏
页码:705 / 710
页数:6
相关论文
共 32 条
[1]  
BUTTURINI A, 1988, BONE MARROW TRANSPL, V3, P185
[2]   GRAFT VERSUS HOST-DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
CHAO, NJ .
CURRENT OPINION IN IMMUNOLOGY, 1992, 4 (05) :571-576
[3]   Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease [J].
Chen, YF ;
Schlegel, PG ;
Tran, NP ;
Thompson, D ;
Zehnder, JL ;
Chao, NJ .
BLOOD, 1997, 89 (04) :1452-1459
[4]   Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8 [J].
Cobbold, SP ;
Adams, E ;
Marshall, SE ;
Davies, JD ;
Waldmann, H .
IMMUNOLOGICAL REVIEWS, 1996, 149 :5-33
[5]  
COHEN P, 1993, J IMMUNOL, V151, P4803
[6]  
FERRARA JLM, 1991, NEW ENGL J MED, V324, P667
[7]   BONE-MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOBLASTIC LEUKEMIA DURING 1ST COMPLETE REMISSION - AN ANALYSIS OF PROGNOSTIC FACTORS [J].
FORMAN, SJ ;
KRANCE, RA ;
ODONNELL, MR ;
NADEMANEE, AP ;
SNYDER, DS ;
FAHEY, JL ;
SCHMIDT, GM ;
ZAIA, JA ;
LIPSETT, JA ;
FINDLEY, DO ;
SNIECINSKI, IJ ;
METTER, GE ;
HILL, LR ;
NATHWANI, MB ;
BLUME, KG .
TRANSPLANTATION, 1987, 43 (05) :650-653
[8]  
HAMILTON BL, 1987, J IMMUNOL, V139, P2511
[9]  
JACOB CO, 1993, IMMUNOGENETICS, V38, P251, DOI 10.1007/BF00188801
[10]   T-CELL PROLIFERATION INVOLVING THE CD28 PATHWAY IS ASSOCIATED WITH CYCLOSPORINE-RESISTANT INTERLEUKIN-2 GENE-EXPRESSION [J].
JUNE, CH ;
LEDBETTER, JA ;
GILLESPIE, MM ;
LINDSTEN, T ;
THOMPSON, CB .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (12) :4472-4481